Al-Bazz, D.Y.; Nelson, A.J.; Burgess, J.; Petropoulos, I.N.; Nizza, J.; Marshall, A.; Brown, E.; Cuthbertson, D.J.; Marshall, A.G.; Malik, R.A.;
et al. Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy? Diagnostics 2022, 12, 731.
https://doi.org/10.3390/diagnostics12030731
AMA Style
Al-Bazz DY, Nelson AJ, Burgess J, Petropoulos IN, Nizza J, Marshall A, Brown E, Cuthbertson DJ, Marshall AG, Malik RA,
et al. Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy? Diagnostics. 2022; 12(3):731.
https://doi.org/10.3390/diagnostics12030731
Chicago/Turabian Style
Al-Bazz, Dalal Y., Andrew J. Nelson, Jamie Burgess, Ioannis N. Petropoulos, Jael Nizza, Anne Marshall, Emily Brown, Daniel J. Cuthbertson, Andrew G. Marshall, Rayaz A. Malik,
and et al. 2022. "Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy?" Diagnostics 12, no. 3: 731.
https://doi.org/10.3390/diagnostics12030731
APA Style
Al-Bazz, D. Y., Nelson, A. J., Burgess, J., Petropoulos, I. N., Nizza, J., Marshall, A., Brown, E., Cuthbertson, D. J., Marshall, A. G., Malik, R. A., & Alam, U.
(2022). Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy? Diagnostics, 12(3), 731.
https://doi.org/10.3390/diagnostics12030731
